Key Highlights

  • Autonomix Medical will receive approximately $2.6 million in gross proceeds after a warrant holder exercised existing warrants to purchase up to 428,731 shares at a reduced exercise price of $6.00 per share.
  • The transaction follows multiple material agreements disclosed by the company in recent periods.
  • The new warrants include ownership caps of 4.99% and, at the holder’s election, may be increased to 9.99%.

Autonomix Medical (NASDAQ: AMIX) has secured a capital infusion of approximately $2.6 million by revising its warrant arrangement. This restructuring converts the earlier Series C warrants into common stock while extending the holder’s opportunity to acquire more equity under the new terms. The additional funding provides the company with a liquidity buffer as it advances its clinical and regulatory programs in the medical‑device sector.

Warrant Terms Reset for Liquidity

Under the revised agreement, the holder exercised all of the existing warrants, thereby purchasing up to 428,731 shares at the newly set price of $6.00 per share. In exchange, Autonomix issued two new warrants, Series D‑1 and Series D‑2, each granting the right to acquire up to 428,731 shares at $5.75 per share. Both warrants carry an exercise term of five and a half years and contain standard anti‑dilution provisions that adjust for stock splits or dividend distributions.

The holder also receives registration rights, obligating the company to file a resale registration statement promptly and to keep it effective for the duration of the warrants. The new warrants incorporate beneficial‑ownership limits designed to prevent excessive concentration. Initially, the holder’s ownership cannot exceed 4.99% of the outstanding shares, but the holder may elect to increase this ceiling to 9.99% under the agreement’s provisions.

Should the required registration statement not remain effective, the warrants provide for a conversion to a cashless exercise mechanism after a prescribed period. Maxim Group acted as the warrant solicitation agent and is entitled to a cash fee equal to 7% of the proceeds, together with a reimbursement of reasonable expenses not to exceed $15,000.

Micro‑Cap Stock Context and Financing Strategy

Autonomix’s shares have experienced notable volatility, trading below recent peaks and reflecting the challenges typical of micro‑cap biotechnology companies. The recent warrant exercise adds a modest amount of capital, which is meaningful for a firm operating in a capital‑intensive field. By lowering the strike price and extending the warrant term, the company signals a focus on immediate financing needs while managing potential dilution.

Investors will be watching the company’s ability to meet upcoming clinical milestones and to sustain its development pipeline.

Next Catalyst: Registration Statement Timeline

The agreement obligates Autonomix to file a resale registration statement for the shares issuable under the new warrants within a short period after execution, with an aim to achieve effectiveness within the timeframe stipulated by the Securities Act. The timing and success of this filing will determine whether the warrants remain exercisable through a cash transaction or transition to a cashless exercise framework, an aspect that may influence investor perception of future dilution and liquidity. Based on the Form 8‑K filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.